"Injection Site Reaction" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Adverse reactions that occur initially at the site of injection or infusion. Milder type is confined to a local allergic flare reaction. A more severe reaction is caused by extravasation of VESICANTS from the blood vessel at the site of injection and can cause damage to the surrounding tissue. In tumor flare reaction symptoms involve well beyond the injection site such as an increase in the tumor size and tumor markers levels, bone pain, and HYPERCALCEMIA.
| Descriptor ID |
D000075662
|
| MeSH Number(s) |
C23.550.340.500 C25.100.781
|
| Concept/Terms |
Injection Site Reaction- Injection Site Reaction
- Injection Site Reactions
- Injection Site Event
- Injection Site Events
- Injection Site Adverse Event
Infusion Site Reaction- Infusion Site Reaction
- Infusion Site Reactions
- Infusion Site Adverse Reaction
- Infusion Site Adverse Event
|
Below are MeSH descriptors whose meaning is more general than "Injection Site Reaction".
Below are MeSH descriptors whose meaning is more specific than "Injection Site Reaction".
This graph shows the total number of publications written about "Injection Site Reaction" by people in this website by year, and whether "Injection Site Reaction" was a major or minor topic of these publications.
Below are the most recent publications written about "Injection Site Reaction" by people in Profiles.
-
Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. N Engl J Med. 2024 Oct 03; 391(13):1179-1192.
-
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery. Eur J Cancer. 2022 11; 176:155-163.
-
Incidence and Characteristics of Delayed Injection Site Reaction to the mRNA-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine (Moderna) in a Cohort of Hospital Employees. Clin Infect Dis. 2022 03 01; 74(4):591-596.
-
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study. J Clin Oncol. 2021 10 20; 39(30):3391-3402.
-
Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase 3, placebo-controlled, multicentre trial. Lancet. 2020 09 05; 396(10252):684-692.
-
A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain. J Invest Dermatol. 2020 08; 140(8):1538-1545.e2.
-
Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis. Gastroenterology. 2020 02; 158(3):562-572.e12.
-
Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult Scler Relat Disord. 2019 May; 30:236-243.
-
Impact of Precipitation of Antibody Therapeutics After Subcutaneous Injection on Pharmacokinetics and Immunogenicity. J Pharm Sci. 2019 06; 108(6):1953-1963.
-
Substance Use Disorder Assessment, Diagnosis, and Management for Patients Hospitalized With Severe Infections Due to Injection Drug Use. J Addict Med. 2019 Jan/Feb; 13(1):69-74.